Literature DB >> 22947919

Clinical features of Pittsburgh compound-B-negative dementia.

Jun Takeuchi1, Hiroyuki Shimada, Suzuka Ataka, Joji Kawabe, Hiroshi Mori, Kei Mizuno, Yasuhiro Wada, Susumu Shiomi, Yasuyoshi Watanabe, Takami Miki.   

Abstract

BACKGROUND/AIMS: We previously found that some cases of clinically diagnosed Alzheimer's disease (AD) were rated as Pittsburgh compound B (PiB) negative by amyloid imaging (i.e. cases of PiB-negative dementia). The present study was designed to analyze the clinical features of PiB-negative dementia patients in detail.
METHODS: Of the 64 cases of clinically diagnosed AD, 14 were rated PiB negative. Eleven of these were further analyzed using CSF biomarker levels and findings from MRI, FDG-PET, (123)I-MIBG myocardial scintigraphy and voxel-based morphometry (VBM).
RESULTS: When examined by (123)I-MIBG myocardial scintigraphy, the heart/mediastinum ratio was significantly higher in the PiB-negative dementia group than in the dementia with Lewy bodies (DLB) group. Analyses of CSF biomarkers and MRI and FDG-PET findings suggested argyrophilic grain disease (AGD) in 3 cases, frontotemporal lobar degeneration (FTLD) in 3 cases, neurofibrillary tangle-predominant dementia (NFTD) in 1 case, and AD in 2 cases. In the VBM data analysis, the PiB-positive AD group showed significant atrophy of both hippocampi compared with the healthy control group, while the PiB-negative dementia group presented with significant atrophy of the left precuneus.
CONCLUSION: PiB-negative dementia is unlikely to include DLB, while it most likely includes diseases of tauopathy, such as FTLD, AGD and NFTD. A better understanding of PiB-negative dementia is expected to further improve the accuracy of the clinical AD diagnosis.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947919     DOI: 10.1159/000341577

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  5 in total

1.  Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.

Authors:  Gaël Chételat; Rik Ossenkoppele; Victor L Villemagne; Audrey Perrotin; Brigitte Landeau; Florence Mézenge; William J Jagust; Vincent Dore; Bruce L Miller; Stéphanie Egret; William W Seeley; Wiesje M van der Flier; Renaud La Joie; David Ames; Bart N M van Berckel; Philip Scheltens; Frederik Barkhof; Christopher C Rowe; Colin L Masters; Vincent de La Sayette; Femke Bouwman; Gil D Rabinovici
Journal:  Brain       Date:  2016-06-29       Impact factor: 13.501

Review 2.  Tau PET imaging in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Ryuichi Harada; Shozo Furumoto; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

Review 3.  Non-Alzheimer's disease-related memory impairment and dementia.

Authors:  Sönke Arlt
Journal:  Dialogues Clin Neurosci       Date:  2013-12       Impact factor: 5.986

4.  Added Diagnostic Value of (11)C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis.

Authors:  K S Frederiksen; S G Hasselbalch; A-M Hejl; I Law; L Højgaard; G Waldemar
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-12-13

5.  Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography.

Authors:  M Degerman Gunnarsson; M Lindau; A F Santillo; A Wall; H Engler; L Lannfelt; H Basun; L Kilander
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.